- Biocon Biologics announces successful Phase 3 study results for Yesintek™, a biosimilar to Ustekinumab, for treating chronic plaque psoriasis.
- The study showed equivalent efficacy, sa…
Join the vibrant privacy-ensured Dzambhala community on
Want to give feedback on this story? Write to us at [email protected]